ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Clinical efficacy comparison of Doxycycline versus Azithromycin combined with Methylprednisolone in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of doxycycline treatment with time to first documented MP-RNA negative conversion in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study.Italian journal of pediatrics · 2026Article
- Analysis of Clinical Characteristics and Risk Factors of Pediatric Macrolide-ResistantInfection and drug resistance · 2026Article
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe escalating prevalence of macrolide-resistant Mycoplasma pneumoniae (MRMP) in China has posed substantial challenges for pediatricians managing mycoplasma pneumoniae pneumonia (MPP). This study aimed to compare the clinical efficacy and prognostic outcomes between two treatment strategies for pediatric patients with macrolide-unresponsive mycoplasma pneumoniae pneumonia (MUMPP) following initial 72-hour intravenous azithromycin therapy: (1) continuation of intravenous azithromycin combined with methylprednisolone, versus (2) switch to oral doxycycline monotherapy.
methodsWe performed a retrospective analysis of children hospitalized for MPP at our institution between November 2023 and October 2024. Children with MPP who showed no clinical response to an initial 72-hour course of intravenous azithromycin were assigned to two groups: (1) intravenous azithromycin combined with methylprednisolone (AZM + methylprednisolone group), and (2) doxycycline monotherapy (DXC group). Clinical efficacy and prognosis were compared between groups using 1:1 propensity score matching (PSM) to adjust for baseline confounding, followed by calculation of statistical power for the primary outcomes.
resultsA total of 1,112 children with MPP were screened, of whom 493 (44.33%) met the criteria for MUMPP, and 382 were included in the final analysis. The DXC group showed a significantly higher rate of pulmonary imaging improvement at discharge compared to the AZM + methylprednisolone group (94.29%vs.77.14%, P < 0.05). No significant intergroup differences were observed in the time to fever resolution or cough relief (P > 0.05). The AZM + methylprednisolone group had a significantly longer hospital stay than the DXC group [8 (7, 9) days vs. 6 (5, 7) days, P < 0.05]. Additionally, the refractory rate was higher in the AZM + methylprednisolone group (14.29% vs. 4.29%, P < 0.05). At 3-month follow-up, the incidence of new infections or diseases was significantly higher in the AZM + methylprednisolone group (32.86% vs. 4.29%, P < 0.05), whereas no significant difference was found in the complete imaging absorption rate between groups within 3 months (98.57% vs. 94.29%,P > 0.05). Notably, no cases of tooth discoloration-related adverse reactions were observed in the DXC group.
conclusionFor pediatric cases of MUMPP, doxycycline yields superior efficacy over the combination regimen of azithromycin plus methylprednisolone in improving radiological findings at discharge, shortening hospital stays, reducing the rate of refractory disease, and lowering the incidence of post-discharge recurrent infection or disease exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.